Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enalapril Maleate

FDA-approved product (tablet, oral), marketed as Enalapril Maleate, Epaned, Epaned Kit and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Enalapril Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enalapril Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enalapril Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Genetic Determinants of ACEI Prodrug Activation

    NCT03051282 · start 2017-04-01

    Registered record
    Registry ID
    NCT03051282
    Conditions
    Healthy Volunteers
    Interventions
    Enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2026-01-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionEnalapril
    PhasePhase 4
    Registry statusCompleted

  • Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.

    NCT03667131 · start 2017-02-13

    Registered record
    Registry ID
    NCT03667131
    Conditions
    Rheumatoid Arthritis
    Interventions
    Enalapril Maleate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-02-13
    Completion
    2018-02-19
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionEnalapril Maleate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study

    NCT03071653 · start 2016-11-24

    Registered record
    Registry ID
    NCT03071653
    Conditions
    Dilated Cardiomyopathy; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy
    Interventions
    Left Cardiac Sympathetic Denervation (LCSD); Optimal Medical Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2016-11-24
    Completion
    2022-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDilated Cardiomyopathy; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy
    InterventionLeft Cardiac Sympathetic Denervation (LCSD); Optimal Medical Therapy
    PhasePhase 2
    Registry statusSuspended

  • Bariatric Surgery and Pharmacokinetics of Enalapril

    NCT03460366 · start 2016-11-02

    Registered record
    Registry ID
    NCT03460366
    Conditions
    Obesity, Morbid
    Interventions
    Enalapril
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2016-11-02
    Completion
    2026-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity, Morbid
    InterventionEnalapril
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

    NCT02874794 · start 2016-08-17

    Registered record
    Registry ID
    NCT02874794
    Conditions
    Heart Failure and Reduced Ejection Fraction
    Interventions
    LCZ696 (sacubitril/valsartan); Enalapril; Placebo of Enalapril; Placebo of LCZ696
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-17
    Completion
    2019-01-26
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure and Reduced Ejection Fraction
    InterventionLCZ696 (sacubitril/valsartan); Enalapril; Placebo of Enalapril; Placebo of LCZ696
    PhasePhase 4
    Registry statusCompleted

  • Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

    NCT03179163 · start 2016-07-20

    Registered record
    Registry ID
    NCT03179163
    Conditions
    Hypertension,Essential
    Interventions
    Captopril Pill; Enalapril Pill; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-07-20
    Completion
    2022-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension,Essential
    InterventionCaptopril Pill; Enalapril Pill; Hydrochlorothiazide
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

    NCT02554890 · start 2016-04-29

    Registered record
    Registry ID
    NCT02554890
    Conditions
    Acute Heart Failure
    Interventions
    sacubitril/valsartan (LCZ696); Enalapril; sacubitril/valsartan (LCZ696) matching placebo; enalapril matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-04-29
    Completion
    2018-07-24
    Enrolment
    887

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure
    Interventionsacubitril/valsartan (LCZ696); Enalapril; sacubitril/valsartan (LCZ696) matching placebo; enalapril matching placebo
    PhasePhase 4
    Registry statusCompleted

  • Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

    NCT02652741 · start 2016-01

    Registered record
    Registry ID
    NCT02652741
    Conditions
    Heart Failure; Congenital Heart Disease
    Interventions
    Enalapril Orodispersible Minitablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Congenital Heart Disease
    InterventionEnalapril Orodispersible Minitablet
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Effect of DPP4 Inhibition on Vasoconstriction

    NCT02639637 · start 2015-12

    Registered record
    Registry ID
    NCT02639637
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin; Placebo; Neuropeptide Y; Enalaprilat; Valsartan 160mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-12
    Completion
    2017-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin; Placebo; Neuropeptide Y; Enalaprilat +1 more
    PhasePhase 4
    Registry statusCompleted

  • The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

    NCT02623036 · start 2015-11

    Registered record
    Registry ID
    NCT02623036
    Conditions
    Hypertension, Resistant to Conventional Therapy
    Interventions
    Equivalent dose enalapril; Equivalent dose lisinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2018-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Resistant to Conventional Therapy
    InterventionEquivalent dose enalapril; Equivalent dose lisinopril
    PhasePhase 1
    Registry statusUnknown

  • Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction

    NCT02468232 · start 2015-06-15

    Registered record
    Registry ID
    NCT02468232
    Conditions
    Heart Failure With Reduced Ejection Fraction (HF-rEF)
    Interventions
    LCZ696; Enalapril; Placebo to LCZ696; Placebo to Enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06-15
    Completion
    2021-02-18
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction (HF-rEF)
    InterventionLCZ696; Enalapril; Placebo to LCZ696; Placebo to Enalapril
    PhasePhase 3
    Registry statusCompleted

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy

    NCT01631409 · start 2013-09

    Registered record
    Registry ID
    NCT01631409
    Conditions
    Coronary Heart Disease (CHD)
    Interventions
    Treatment of CHD risk factors; Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.; Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.; PCA; CABG; Cardiospec; Aspirin, Isosorbide mononitrate, Atenolol, Enalapril
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2021-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease (CHD)
    InterventionTreatment of CHD risk factors; Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.; Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.; PCA +3 more
    PhaseNot recorded
    Registry statusWithdrawn

  • Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?

    NCT01437371 · start 2011-08

    Registered record
    Registry ID
    NCT01437371
    Conditions
    Heart Failure
    Interventions
    - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2014-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Intervention- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    PhasePhase 3
    Registry statusCompleted

  • Enalapril in Collagen Type 4 Nephropathy

    NCT01465126 · start 2011-01

    Registered record
    Registry ID
    NCT01465126
    Conditions
    Collagen Type-4 Nephropathies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-10
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCollagen Type-4 Nephropathies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted